News

Sandra Duncan, RN, BSN, discusses her transition to clinical research, and what her responsibilities are like supporting the ongoing CheckMate-73L trial.

Real-world evidence recently presented at the 2021 AUA Annual Meeting showed that high adherence rates and favorable prostate-specific antigen (PSA) response were observed in men with nmCRPC who were treated with apalutamide.

A phase 2 trial presented at the 2021 ESMO Annual Congress showed that Balstilimab plus Zalifrelimab induced superior response rates, duration of responses, and overall survival in patients with recurrent/metastatic cervical cancer.

The FDA has approved ruxolitinib to treat adults with steroid-refractory chronic graft-versus-host disease.

An expert presenting at the Society of Hematology Oncology 2021 Annual Conference shared important updates in polycythemia vera (PV) treatment and weighed in on the direction of future treatment.

Data presented at the 2021 ESMO Congress suggest that pembrolizumab in addition to chemo with or without bevacizumab may become new standard of care in the frontline setting of cervical cancer treatment.

Patients with advanced RCC who received prior VEGF-targeted therapy tend to have longer survival outcomes with cabozantinib than with axitinib.

Rechallenge with maintenance olaparib following response to platinum-based chemotherapy significantly improved PFS in heavily pretreated patients with relapsed ovarian cancer.

The FDA approved tisotumab vedotin for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Obese men are more likely to have improved overall survival following treatment for mCRPC than man who are overweight or normal weight, analysis finds.

Interim findings presented at the 2021 ESMO congress suggest that tisotumab vedotin plus frontline carboplatin and second-/third-Line pembrolizumab may be a suitable treatment option for recurrent/metastatic cervical cancer.

A global study revealed that patients and caregivers alike reported insufficient knowledge surrounding renal cell carcinoma.

Between monitoring for medication adherence and ensuring that patients know when to call if their symptoms escalate, oncology nurses are a pivotal factor in decreasing mortality among patients with leukemia, says Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN.

Characteristics such as low positive PD-L1 expression and rare high positive staining were identified in both patients with VHL-mutated and VHL wild type clear cell renal cell carcinoma.

Chevon Rariy, MD, outlines patient eligibility criteria, and the alterations to the nurse patient relationship, as CTCA launches the novel Oncology Clinic at Home Program.

Patients with endometrial cancer and high tumor mutational burden experienced superior overall response rates to the agent dostarlimab than patients with low mutational burden.

“We’ve had periods of time where things were shut down. We do have telemedicine, that was expanded, but telemedicine doesn’t work for everyone. If you don’t have internet access, if you don’t have the ability to understand the technology….”

Patients with nonmetastatic castration-resistant prostate cancer often undergo prolonged treatment periods, making the safety profile of therapies like darolutamide an important factor in optimum treatment selection.

Yoga has a positive impact on the vagus nerve, which influences how people think, remember, and feel, and therefore can improve the mental well-being of patients with prostate cancer.

The FDA has green lit mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with an EGFR exon 20 insertion mutation.

Patients with progressed multiple myeloma experienced deep and durble responses through CAR T-cell therapy ciltacabtagene autoleucel therapy.

Patients with chronic lymphocytic leukemia (CLL) are at an increased risk for infection.

Zanubrutinib received an accelerated approval for the indication of adults with marginal zone lymphoma with at least 1 prior treatment with an anti-CD20-based therapy.

Treating patients with myeloproliferative neoplasms in accelerated phase (MPN-AP) remains an ongoing challenge as there are still no standard therapeutic approaches, says an expert.

Updates from the ongoing S1619 trial suggest that a triplet combination regimen of neoadjuvant cisplatin, pemetrexed, and atezolizumab is effective and tolerable in the treatment of patients with resectable pleural mesothelioma.

Due to the favorable efficacy and safety profiles of daratumumab plus lenalidomide and dexamethasone, researchers speculate that the combination may become the new standard of care in multiple myeloma treatment.

Researchers identified a slower rate of health-related quality of life deterioration, as well as an ability to postpone locally invasive procedures, in patients with nonmetastatic castration-resistant prostate cancer who received darolutamide.

Patients with myeloma and a negative MRD may be at a reduced risk of mortality and other progression-free survival events.

Patients with both COVID-19 and malignant pleural mesothelioma showed high rates of hospitalization and mortality.

While survival rates in T-cell acute lymphoblastic leukemia remain around 90%, researchers are optimistic that the use of targeted therapies and immunotherapies will continue to improve treatment options.